| 000 | 02548nam a22003137a 4500 | ||
|---|---|---|---|
| 003 | OSt | ||
| 005 | 20240305193735.0 | ||
| 008 | 221123b |||||||| |||| 00| 0 eng d | ||
| 028 | _b Phone: +255 28 298 3384 | ||
| 028 | _b Fax: +255 28 298 3386 | ||
| 028 | _bEmail: vc@bugando.ac.tz | ||
| 028 | _b Website: www.bugando.ac.tz | ||
| 040 |
_bEnglish _cDLC |
||
| 041 | _aEnglish | ||
| 100 |
_aPaulina Manyiri _922702 |
||
| 222 | _aMycobacteremia Mortality Fever HIV | ||
| 245 | _aPrevalence and factors associated with Mycobacteremia and mortality among febrile HIV infected patients in Mwanza, Tanzania | ||
| 260 |
_aMwanza, Tanzania: _b Elsevier & _b Catholic University of Health and Allied Sciences [CUHAS – Bugando] _c2018/5/1 |
||
| 300 | _a Pages 69-71 | ||
| 490 | _v International Journal of Infectious Diseases Volume 70 | ||
| 520 | _aAbstract: Objectives: This study investigated the prevalence and factors associated with mycobacteremia and mortality among febrile HIV infected patients in developing countries. Methods: A hospital based cross-sectional study was conducted among febrile HIV patients admitted at Bugando Medical centre and Sekou Toure hospital between November 2016 and March 2017. Blood culture was done on BACTEC Myco/F Lytic bottles. Clinical and demographic data were collected using a pre-tested data collection tool. Results: A total of 154 patients with the mean age of 41.5 ± 12.2 were enrolled. Females formed the majority, 93 (60%) of the study participants. The prevalence of Mycobacteremia was 3.3% while that of other bacteria was 8.4%. Age (p = 0.03), recent HIV diagnosis (p = 0.005), not taking HAART (p = 0.031) and low CD4+ count (p = 0.002) were significantly associated with Mycobacteremia. Factors significantly associated with 14-day in-hospital mortality were advanced HIV infection (p < 0.001), poor ART adherence (p < 0.001), low CD4+ (p = 0.0002) and Mycobacteremia (p = 0.007). Conclusion: The prevalence of Mycobacteremia was low; however, it was significantly associated with mortality. Mycobacteremia should be suspected in high risk febrile HIV infected individuals followed by early appropriate treatment in order to reduce associated morbidity and mortality. | ||
| 700 |
_a Rodrick Kabangila _923057 |
||
| 700 |
_a Christa Kasang _923005 |
||
| 700 |
_aMartha F Mushi _919663 |
||
| 700 |
_aMariam M Mirambo _922927 |
||
| 700 |
_a Stephen E Mshana _915820 |
||
| 856 | _uhttps://doi.org/10.1016/j.ijid.2018.03.009 | ||
| 942 |
_2ddc _cVM |
||
| 999 |
_c19649 _d19649 |
||